The metabolic syndrome: time for a critical appraisal
Tóm tắt
Từ khóa
Tài liệu tham khảo
Avogaro P, Crepaldi G, Enzi G, Tiengo A (1967) Associazione di iperlidemia, diabete mellito e obesita di medio grado. Acto Diabetol Lat 4:36–41
Haller H (1977) Epidemiology and associated risk factors of hyperlipoproteinemia. Z Gesamte Inn Med 32:124–128
Singer P (1977) Diagnosis of primary hyperlipoproteinemias. Z Gesamte Inn Med 32:129–133
Himsworth H (1936) Diabetes mellitus: a differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1:127–130
Shen S-W, Reaven GM, Farquhar JW (1970) Comparison of impedance to insulin mediated glucose uptake in normal and diabetic subjects. J Clin Invest 49:2151–2160
Ginsburg H, Kimmerling G, Olefsky JM, Reaven GM (1975) Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. J Clin Invest 55:454–461
Reaven GM, Lerner R, Stern M, Farquhar JW (1967) Role of insulin in endogenous hypertriglyceridemia. J Clin Invest 46:1756–1767
Olefsky JM, Farquhar JW, Reaven GM (1974) Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med 57:551–560
Orchard TJ, Becker DJ, Bates M, Kuller LH, Drash AL (1983) Plasma insulin and lipoprotein concentrations: an atherogenic association? Am J Epidemiol 118:326–337
Olefsky JM, Kolterman OG, Scarlett JA (1982) Insulin action and resistance in obesity and non-insulin-dependent type II diabetes mellitus. Am J Physiol 243:E15–E30
Stern MP, Haffner SM (1986) Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis 6:123–130
Modan M, Halkin H, Almog S et al (1985) Hyperinsulinemia: a link between hypertension, obesity, and glucose intolerance. J Clin Invest 75:809–817
Haffner SM, Fong D, Hazuda HP, Pugh JA, Patterson JK (1988) Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabetics. Metabolism 37:338–345
Ferrannini E, Buzzigoli G, Bonadonna R et al (1987) Insulin resistance in essential hypertension. N Engl J Med 317:350–357
Wingard DL, Barrett-Connor E, Criqui MH, Suarez L (1983) Clustering of heart disease risk factors in diabetic compared to non-diabetic adults. Am J Epidemiol 117:19–26
Zavaroni I, Bonora E, Pagliara M et al (1989) Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 320:502–506
Ferrannini E, Haffner SM, Mitchell BD, Stern MP (1991) Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 34:416–422
Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP (1992) Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41:715–722
Mykkanen L, Kuusisto J, Pyorala K, Laakso M (1993) Cardiovascular disease risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects. Diabetologia 36:553–559
Schmidt MI, Duncan BB, Watson RL, Sharrett AR, Brancati FL, Heiss G A (1996) metabolic syndrome in whites and African-Americans. The Atherosclerosis Risk in Communities baseline study. Diabetes Care 19:414–418
Laakso M, Sarlund H, Mykkanen L (1990) Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 10:223–231
Schmidt MI, Watson RL, Duncan BB et al (1996) Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators. Metabolism 45:699–706
Meigs JB, D’Agostino RB, Wilson PWF, Cupples LA, Nathan DM, Singer DE (1997) Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes 46:1594–1600
Liese AD , Mayer-Davis EJ, Haffner SM (1998) Development of the multiple metabolic syndrome: an epidemiologic perspective. Epidemiol Rev 20:157–172
World Health Organization (1999) Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO consultation. World Health Organization, Geneva
Expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (2001) Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497
Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433–438
Balkau B, Charles MA, Drivsholm T et al (2002) Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. European Group for the Study of Insulin Resistance (EGIR). Diabetes Metab 28:364–376
Einhorn D, Reaven GM, Cobin RH et al (2003) American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9:237–252
Wilson PWF, Grundy SM (2003) The metabolic syndrome. Practical guide to origins and treatment: Part I. Circulation 108:1422–1425
Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA (2004) Clinical management of metabolic syndrome. Circulation 109:551–556
Lakka HM, Laaksonen DE, Lakka TA et al (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716
McNeill AM, Rosamond WD, Girman CJ et al (2005) The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28:385–390
Stern SE, Williams K, Ferrannini E, Defronzo RA, Bogardus C, Stern MP (2005) Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 54:333–339
Ford ES, Giles WH (2003) A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 26:575–581
Meigs JB, Wilson PW, Nathan DM, D’Agostino RB Sr, Williams K, Haffner SM (2003) Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 52:2160–2167
Lempiainen P, Mykkanen L, Pyorala K, Laakso M, Kuusisto J (1999) Insulin resistance syndrome predicts coronary heart disease events in elderly non-diabetic men. Circulation 100:123–128
Kekalainen P, Sarlund H, Pyorala K, Laakso M (1999) Hyperinsulinemia cluster predicts the development of type 2 diabetes independent of a family history of diabetes. Diabetes Care 22:86–92
Pyorala M, Miettinen H, Halonen P, Laakso M, Pyorala K (2000) Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 20:538–544
Kuusisto J, Lempiainen P, Mykkanen L, Laakso M (2001) Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men. Diabetes Care 24:1629–1633
Isomaa B, Almgren P, Tuomi T et al (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689
Onat A, Ceyhan K, Basar O, Erer B, Tobrak S, Sansoy V (2002) Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels—a prospective and cross-sectional evaluation. Atherosclerosis 165:285–292
Alexander CM, Landsman PB, Teutsch SM, Haffner SM (2003) NCEP metabolic syndrome, diabetes mellitus and prevalence of coronary heart disease. Diabetes 52:1210–1214
Katzmarzyk PT, Church TS, Blair SN (2004) Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med 164:1092–1097
Ford ES (2004) The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 173:309–314
Girman CJ, Rhodes T, Mercuri M et al (2004) The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 93:136–141
Malik S, Wong ND, Franklin SS et al (2004) Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease and on all causes in United States adults. Circulation 110:1245–1250
Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP (2004) National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110:1251–1257
Scuteri A, Najjar S, Morrell C, Lakatta E (2005) The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events. Diabetes Care 28:882–887
Bruno G, Merletti F, Biggeri A et al (2004) Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 27:2689–2694
Resnick HE, Jones K, Ruotolo G et al (2003) Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in non-diabetic American Indians: the Strong Heart Study. Diabetes Care 26:861–867
Marroquin OC, Kip KE, Kelley DE et al (2004) Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women’s Ischemia Syndrome Evaluation. Circulation 109:714–721
Fuller JH , Shipley MJ, Rose G, Jarrett RJ, Keen H (1980) Coronary heart disease risk and impaired glucose tolerance: the Whitehall Study. Lancet 1:1373–1376
Lippel K, Tyroler H, Eder H, Gotto A, Vahouny G (1981) Relationship of hypertriglyceridemia to atherosclerosis. Atherosclerosis 1:406–417
Miller GJ, Miller NE (1975) Plasma high density lipoprotein concentration and development of ischemic heart disease. Lancet 1:16–19
Keys A, Aravanis C, Blackburn H et al (1972) Coronary heart disease: overweight and obesity as risk factors. Ann Intern Med 77:15–27
Deckert T, Feldt-Rasmussen B, Jensen T, Kofoed-Enevoldsen A (1989) Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia 32:219–226
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet 360:1903–1913
Kannel WB, McGee DL (1979) Diabetes and cardiovascular risk factors in the Framingham study. Circulation 59:8–13
Rosengren A, Welin L, Tsipigianni A, Wilhelmsen L (1989) Impact of cardiovascular risk factors on coronary heart disease and mortality among middle-aged diabetic men: a general population study. Br Med J 299:1127–1131
Stamler J, Vaccaro O , Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434–444
Danesh J, Collins R, Appleby P, Peto R (1998) Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279:1477–1482
Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836–843
Ridker PM (2003) Clinical applications of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107:363–369
Ridker PM, Cannon CP, Morrow D et al (2005) C-reactive protein levels and outcomes after statin therapy. Pravastatin or Atorvastatin Evaluation and Infection Therapy—Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). N Engl J Med 352:20–28
Ridker PM, Buring JE, Cook NR, Rifai N (2003) C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107:391–397
Pradhan AD, Cook NR, Buring JE, Manson JE, Ridker PM (2003) C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol 23:650–655
Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972–978
McLaughlin T, Abbasi F, Lamendola C et al (2002) Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 106:2908–2912
Festa A, D’Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42–47
Sattar N, Gaw A, Scherbakova O et al (2003) Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108:414–419
Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW (2004) C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110:380–385
Reilly MP, Wolfe ML, Rhodes T, Girman C, Mehta N, Rader DJ (2004) Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 110:803–809
Ridker PM, Wilson PW, Grundy SM (2004) Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 109:2818–2825
Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148:209–214
Xu H, Barnes GT, Yang Q et al (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821–1830
Wellen KE, Hotamisligil GS (2003) Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112:1785–1788
Pearson TA, Mensah GA, Alexander RW et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511
Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556
Weyer C, Funahashi T, Tanaka S et al (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935
Chandran M, Phillips SA, Ciaraldi T, Henry RR (2003) Adiponectin: more than just another fat cell hormone? Diabetes Care 26:2442–2450
Matsubara M, Maruoka S, Katayose S (2002) Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 87:2764–2769
Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G (2002) Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 25:971–976
Kumada M, Kihara S, Sumitsuji S et al (2003) Association of hypoadiponectinemia with coronary artery disease in men. Osaka CAD Study Group. Coronary artery disease. Arterioscler Thromb Vasc Biol 23:85–89
Kojima S, Funahashi T, Sakamoto T et al (2003) The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart 89:667–672
Zoccali C, Mallamaci F, Tripepi G et al (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134–141
Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730–1737
Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE (1993) The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42:945–949
Haffner SM, D’Agostino R Jr, Mykkanen L et al (1999) Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 22:562–568
Festa A, D’Agostino R Jr, Mykkanen L et al (1999) Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 19:562–568
Ernst E, Resch KL (1993) Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 18:956–963
Imperatore G, Riccardi G, Iovine C, Rivellese AA, Vaccaro O (1998) Plasma fibrinogen: a new factor of the metabolic syndrome. A population-based study. Diabetes Care 21:649–654
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847
Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM (2004) Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 27:2676–2681 (‘Erratum’ in Diabetes Care 28:238, 2005)
Klein BE, Klein R, Lee KE (2002) Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care 25:1790–1794
Golden SH, Folsom AR, Coresh J, Sharrett AR, Szklo M, Brancati F (2002) Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. Diabetes 51:3069–3076
Stevens RJ, Kothari V, Adler AI, Stratton IM (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). United Kingdom Prospective Diabetes Study (UKPDS) Group. Clin Sci 101:671–679
Stern MP, Williams K, Hunt KJ (2005) Impact on diabetes/metabolic syndrome in patients with established cardiovascular disease. Atheroscler Suppl 6:3–6
Yarnell JWG, Patterson CC, Bainton D, Sweetnam PM (1998) Is metabolic syndrome a discrete entity in the general population? Evidence from the Caerphilly and Speedwell population studies. Heart 79:248–252
Song SH, Brown PM (2004) Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet Med 21:238–245
McEwan P, Williams JE, Griffiths JD et al (2004) Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabet Med 21:318–323
Pyorala K (1979) Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 2:131–141
Welborn TA, Wearne K (1979) Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 2:154–160
Fontbonne A, Charles MA, Thibult N et al (1991) Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 34:356–361
Moller LF, Jespersen J (1995) Fasting serum insulin levels and coronary heart disease in a Danish cohort: 17-year follow-up. J Cardiovasc Risk 2:235–240
Perry IJ, Wannamethee SG, Whincup PH, Shaper AG, Walker MK, Alberti KG (1996) Serum insulin and incident coronary heart disease in middle-aged British men. Am J Epidemiol 144:224–234
Despres JP, Lamarche B, Mauriege P et al (1996) Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952–957
Pyorala M, Miettinen H, Laakso M, Pyorala K (1998) Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation 98:398–404
Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G (1980) Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 19:205–210
Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH (1997) A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 20:935–942
Yip J, Facchini FS, Reaven GM (1998) Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 83: 2773–2776
Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K (1990) 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin dependent diabetic and non-diabetic subjects. Circulation 82:27–36
Hu G, Qiao Q, Tuomilehto J, Eliasson M, Feskens EJ, Pyorala K (2004) Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies. DECODE Insulin Study. Diabetologia 47:1245–1256
Welin L, Eriksson H, Larsson B, Ohlson LO, Svardsudd K, Tibblin K (1992) Hyperinsulinaemia is not a major coronary risk factor in elderly men. The study of men born in 1913. Diabetologia 35:766–770
Orchard TJ, Eichner J, Kuller LH, Becker DJ, McCallum LM, Grandits GA (1994) Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype. A report from the Multiple Risk Factor Intervention Trial. Ann Epidemiol 4:40–45
Ferrara A, Barrett-Connor EL, Edelstein SL (1994) Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo Study, 1984–1991. Am J Epidemiol 140:857–869
Stern MP (1994) The insulin resistance syndrome: the controversy is dead, long live the controversy! Diabetologia 37:956–958
Wingard DL, Barrett-Connor EL, Ferrara A (1995) Is insulin really a heart disease risk factor? Diabetes Care 18:1299–1304
McKeigue P, Davey G (1995) Associations between insulin levels and cardiovascular disease are confounded by comorbidity. Diabetes Care 18:1294–1298
Robbins DC, Andersen L, Bowsher R et al (1996) Report of the American Diabetes Association’s Task Force on standardization of the insulin assay. Diabetes 45:242–256
Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM (2000) Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy non-diabetic volunteers. Diabetes Care 23:171–175
Facchini FS, Hua N, Abbasi F, Reaven GM (2001) Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 86:3574–3578
Mykkanen L, Haffner SM, Ronnemaa T, Bergman RN, Laakso M (1997) Low insulin sensitivity is associated with clustering of cardiovascular disease risk factors. Am J Epidemiol 146:315–321
Weyer C, Hanson RL, Tataranni PA, Bogardus C, Pratley RE (2000) A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes 49:2094–2101
McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G (2003) Use of metabolic markers to identify overweight individuals who are insulin-resistant. Ann Intern Med 139:802–809
Liao Y, Kwon S, Shaughnessy S et al (2004) Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 27:978–983
Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES (2004) Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 53:1195–1200
Laakso M, Sarlund H, Salonen R et al (1991) Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb 11:1068–1076
Agewall S, Fagerberg B, Attvall S, Wendelhag I, Urbanavicius V, Wikstrand J (1995) Carotid artery wall intima–media thickness is associated with insulin-mediated glucose disposal in men at high and low coronary risk. Stroke 26:956–960
Howard G, O’Leary DH, Zaccaro D et al (1996) Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 93:1809–1817
Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP (2000) Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 101:975–980
DeFronzo RA (1988) Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667–687
Mardia KV, Kent JT, Bibby JM (1979) Factor analysis. In: Mardia KV, Kent JT, Bibby JM (eds) Multivariate analysis. Academic, London pp 255–280
Cureton EE, D’Agostino RB (1986) Factor analysis: an applied approach. Lawrence Erlbaum Associates, Hillsdale NJ
Krzanowski WJ (1994) Explaining observed associations: latent-variable models. In: Krzanowski WJ (ed) Principles of multivariate statistical methods. A primer. Chapman and Hall, London, pp 93–106
Lawlor DA, Ebrahim S, May M, Davey Smith G (2004) (Mis)use of factor analysis in the study of insulin resistance syndrome. Am J Epidemiol 159:1013–1018
Gray RS, Fabsitz RR, Cowan LD, Lee ET, Howard BV, Savage PJ (1998) Risk factor clustering in the insulin resistance syndrome. The Strong Heart Study. Am J Epidemiol 148:869–878
Lehto S, Ronnemaa T, Pyorala K, Laakso M (2000) Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with Type II diabetes. Diabetologia 43:148–155
Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP (2000) Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 152:897–907
Maison P, Byrne CD, Hales CN, Day NE, Wareham NJ (2001) Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care 24:1758–1763
Hanley AJ, Karter AJ, Festa A et al (2002) Factor analysis of metabolic syndrome using directly measured insulin sensitivity: the insulin resistance atherosclerosis study. Diabetes 51:2642–2647
Wang JJ, Qiao Q, Miettinen ME, Lappalainen J, Hu G, Tuomilehto J (2004) The metabolic syndrome defined by factor analysis and incident type 2 diabetes in a Chinese population with high postprandial glucose. Diabetes Care 27:2429–2437
Ford ES (2003) Factor analysis and defining the metabolic syndrome. Ethn Dis 13:429–437
Shen BJ, Todaro JF, Niaura R et al (2003) Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am J Epidemiol 157:701–711
Laws A, Reaven GM (1992) Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med 231:25–30
Carr DB, Utzschneider KM, Hull RL et al (2004) Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53:2087–2094
Pyorala K, Ballantyne CM, Gumbiner B et al (2004) Reduction of cardiovascular events by simvastatin in non-diabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 27:1735–1740
UKPDS Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:854–865
Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group. N Engl J Med 346:393–403
Shadid S, Jensen MD (2003) Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 26:3148–3152
Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI (2001) Rosiglitazone monotherapy is effective in patients with type 2 diabetes. Rosiglitazone Clinical Trials Study Group. J Clin Endocrinol Metab 86:280–288
Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL (2000) Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The pioglitazone 001 study group. Diabetes Care 23:1605–1611
Freed MI, Ratner R, Marcovina SM et al (2002) Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Rosiglitazone study 108. Am J Cardiol 90:947–952
Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI (2002) Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679–684
Satoh N, Ogawa Y, Usui T et al (2003) Anti-atherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26:2493–2499
Davidson MB (2003) Is treatment of insulin resistance beneficial independent of glycemia? Diabetes Care 26:3184–3186
Chobanian AV, Bakris GL, Black HR et al (2003) Seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42:1206–1252
Smith SC Jr, Jackson R, Pearson TA et al (2004) Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the world heart and stroke forum. Circulation 109:3112–3121
International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org (accessed 2 June 2005)
Washington Post (2005) New diagnosis for overweight. Major risk factors add up to ‘metabolic syndrome’. Washington Post 8 February 2005: Sect. A, p1
No authors listed (2000) Stedman’s medical dictionary, 27th edition. Lippincott, Williams and Wilkins, Baltimore, pp 1746